The presence of pre-existing HLA antibodies in blood donors has been implicated in Transfusion-Related Acute Lung Injury (TRALI) and TRALI-like transfusion reactions in the recipients of blood products from sensitized donors. TRALI is a syndrome that is described as a spectrum of clinical symptoms that occur very rapidly (usually in 1-2 hours) following transfusion with blood products. Occurring in a small number of patients that receive blood products, it remains the leading cause of transfusion-related deaths reported to the Food and Drug Administration.
DonorScreen-HLA® Class I and Class II assay
The Clear Choice for HLA Antibody Detection.
Your laboratory’s solution for testing blood products for HLA antibodies demonstrates your commitment to keeping blood transfusions safe.
Immucor’s DonorScreen-HLA® Class I and Class II assay offers a reliable, accurate and cost effective screening for HLA antibodies to help maintain your donor base while improving patient outcomes. Our assay has been specifically designed to detect these antibodies in blood donors using the STRATEC BIOMEDICAL AG® GEMINI (GEMINI) automated ELISA processing instrument.1
- GEMINI automation allows for screening of 88 donor samples for both Class I and Class II HLA antibodies in a single run.
- Most kit reagents are ready-to-use and can be directly placed on the instrument
- Automation provides walk-away use
- Can use donor samples stored for up to 96 hours at room temperature in primary collection tube
- Can use either plasma or sera
- System accepts eight (8) barcodes at one time, including: Code 128, Code 39, Pharmacode, Codabar
- Barcoded reagent bottles eliminate set-up mistakes
- Barcode reading of donor sample tubes provides data traceability
1 LIFECODES DonorScreen-HLA® Class I and Class II assay for in vitro diagnostic use [package insert], Waukesha, WI; Immucor GTI Diagnostics, Inc., 2018.